| Dr Ted M Kremer, MD | |
|
55 Lake Ave N, Department Of Pediatric Pulmonary Medicine, Worcester, MA 01655-0002 | |
| (774) 441-8086 | |
| (774) 441-8071 |
| Full Name | Dr Ted M Kremer |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 26 Years |
| Location | 55 Lake Ave N, Worcester, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760464184 | NPI | - | NPPES |
| 110036698A | Medicaid | MA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Umass Memorial Medical Group Inc | 4284539891 | 1889 |
News Archive
Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus's propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
A team of researchers may have found a way to block gonorrhea infection by blocking bacterial pathogen from using zinc, an essential mineral found in many food sources.
Researchers from the Baylor College of Medicine and the Texas Heart Institute have discovered a new way to dramatically improve heart repair. The future goal is to use this knowledge to combat human cardiovascular disease by improving repair after a heart attack. The research has just been published in the scientific journal Development.
Consumers spend an average of 10 hours researching a new car, but only one hour or less reviewing their health benefit options in open enrollment season which begins this fall for millions of Americans.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
› Verified 3 days ago
| Entity Name | Umass Memorial Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760445373 PECOS PAC ID: 4284539891 Enrollment ID: O20040113000267 |
News Archive
Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus's propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
A team of researchers may have found a way to block gonorrhea infection by blocking bacterial pathogen from using zinc, an essential mineral found in many food sources.
Researchers from the Baylor College of Medicine and the Texas Heart Institute have discovered a new way to dramatically improve heart repair. The future goal is to use this knowledge to combat human cardiovascular disease by improving repair after a heart attack. The research has just been published in the scientific journal Development.
Consumers spend an average of 10 hours researching a new car, but only one hour or less reviewing their health benefit options in open enrollment season which begins this fall for millions of Americans.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ted M Kremer, MD Po Box 415348, Boston, MA 02241-0001 Ph: (800) 225-8885 | Dr Ted M Kremer, MD 55 Lake Ave N, Department Of Pediatric Pulmonary Medicine, Worcester, MA 01655-0002 Ph: (774) 441-8086 |
News Archive
Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus's propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
A team of researchers may have found a way to block gonorrhea infection by blocking bacterial pathogen from using zinc, an essential mineral found in many food sources.
Researchers from the Baylor College of Medicine and the Texas Heart Institute have discovered a new way to dramatically improve heart repair. The future goal is to use this knowledge to combat human cardiovascular disease by improving repair after a heart attack. The research has just been published in the scientific journal Development.
Consumers spend an average of 10 hours researching a new car, but only one hour or less reviewing their health benefit options in open enrollment season which begins this fall for millions of Americans.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
› Verified 3 days ago
Marissa E Parrillo, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 774-442-5545 Fax: 774-443-7042 | |
Dr. Penny M. Feldman, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 774-441-8081 Fax: 774-441-8055 | |
Dr. Linda D Sagor, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Lake Ave N, Department Of Pediatrics, Worcester, MA 01655 Phone: 508-856-4198 Fax: 508-856-1042 | |
Dr. Robert W Zavoski, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 26 Queen Street, Worcester, MA 01610 Phone: 508-860-7800 Fax: 508-860-7925 | |
Cornelius T Tyrrell, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Lake Ave N, Department Of Pediatrics, Worcester, MA 01655 Phone: 508-334-7986 Fax: 508-334-7989 | |
Callie M Stone, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 508-334-1000 | |
Nura El-haj, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 774-441-8083 Fax: 774-441-8057 |